Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients

Journal of Pediatrics

Volumn 163, Issue 3, 2013, Pages

  Davidson, Geoffrey ^a,b   Wenzl, Tobias G ^c   Thomson, Michael ^d   Omari, Taher ^a,b   Barker, Peter ^e   Lundborg, Per ^f   Illueca, Marta ^e  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

AE Adverse event GER Gastroesophageal reflux GERD Gastroesophageal reflux disease LSM Least square mean ITT Intent to treat PPI Proton pump inhibitor SAE Serious adverse event

Indexed keywords

ESOMEPRAZOLE;

APNEA; ARTICLE; BODY HEIGHT; BODY WEIGHT; BRADYCARDIA; CONTROLLED STUDY; CRYING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL PH MONITORING; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GESTATIONAL AGE; HEAD CIRCUMFERENCE; HUMAN; IMPEDANCE; INFANT; INFECTION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; OXYGEN DESATURATION; OXYGEN SATURATION; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIDEORECORDING; VITAL SIGN; VOMITING;

EID: 84882853668     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2013.05.007     Document Type: Article

References (18)

1. C.D. Rudolph, L.J. Mazur, G.S. Liptak, R.D. Baker, J.T. Boyle, and R.B. Colletti Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North America Society for Pediatric Gastroenterology and Nutrition J Pediatr Gastroenterol Nutr 32 Suppl 2 2001 S1 S31
2. Y. Vandenplas, C.D. Rudolph, C. Di Lorenzo, E. Hassall, G. Liptak, and L. Mazur Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) J Pediatr Gastroenterol Nutr 49 2009 498 547
3. P.M. Sherman, E. Hassall, U. Fagundes-Neto, B.D. Gold, S. Kato, and S. Koletzko A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population Am J Gastroenterol 104 2009 1278 1295
4. D.A. Novak Gastroesophageal reflux in the preterm infant Clin Perinatol 23 1996 305 320
5. J. Bishop, M. Furman, and M. Thomson Omeprazole for gastroesophageal reflux disease in the first 2 years of life: a dose-finding study with dual-channel pH monitoring J Pediatr Gastroenterol Nutr 45 2007 50 55
6. NEXIUM (esomeprazole magnesium) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2009.
7. J.J. Barron, H. Tan, J. Spalding, A.W. Bakst, and J. Singer Proton pump inhibitor utilization patterns in infants J Pediatr Gastroenterol Nutr 45 2007 421 427
8. R.J. van der Pol, M.J. Smits, M.P. van Wijk, T.I. Omari, M.M. Tabbers, and M.A. Benninga Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review Pediatrics 127 2011 925 935
9. T.W. Higginbotham Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease Ann Pharmacother 44 2010 572 576
10. M. Illueca, T. Omari, M. Thomson, T.G. Wenzl, T. Stuebe, and B. Harrison Novel integration of video and pH/impedance recording coupled with cardiorespiratory monitoring for evaluation of pediatric gastroesophageal reflux disease (Poster #T2016) Gastroenterology 134 Suppl 1 2008 A-601
11. R.J. Kuczmarski, C.L. Ogden, S.S. Guo, L.M. Grummer-Strawn, K.M. Flegal, and Z. Mei 2000 CDC growth charts for the United States: Methods and development National Center for Health Statistics Vital Health Stat 11 2002 May [updated 2010 June 30]. Available at: http://www.cdc.gov/nchs/data/series/sr-11/sr11-246. pdf Accessed Mar 3, 2010
12. T.I. Omari, P. Lundborg, M. Sanstrom, P. Bondarov, M. Fjellman, and R. Haslam Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease J Pediatr 155 2009 222 228
13. T.I. Omari, R.R. Haslam, P. Lundborg, and G.P. Davidson Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux J Pediatr Gastroenterol Nutr 44 2007 41 44
14. G.M. Comer, J. Kierkus, J.E. Sullivan, W. Furmaga-Jablonska, N.J. Rath, and C. Fu M1908 pharmacodynamics (PD) and safety of pantoprazole delayed-release granules in infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease (GERD) Gastroenterol 136 Suppl 1 2009 A443 A444
15. S.R. Orenstein, E. Hassall, W. Furmaga-Jablonska, S. Atkinson, and M. Raanan Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease J Pediatr 154 2009 514 520
16. H. Winter, T. Gunasekaran, V. Tolia, F. Gottrand, P.N. Barker, and M. Illueca Esomeprazole for the treatment of GERD in infants ages 1-11 months J Pediatr Gastroenterol Nutr 55 2012 14 20
17. R. Farré, K. Blondeau, D. Clement, M. Vicario, L. Cardozo, and M. Vieth Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique Gut 60 2011 885 892
18. C.M. Loots, M.P. Van Wijk, M.J. Smits, T.G. Wenzl, M.A. Benninga, and T.I. Omari Measurement of mucosal conductivity by MII is a potential marker of mucosal integrity restored in infants on acid-suppression therapy J Pediatr Gastroenterol Nutr 53 2011 120 123